📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

REFINE (REduced Frequency ImmuNE checkpoint inhibition in cancers): A multi-arm phase II basket trial testing reduced intensity immunotherapy across different cancers. (2023)

First Author: Merrick S

Attributed to: Developing Existing Healthcare Technologies to Deliver More Affordable and Effective Cancer Care funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.cct.2022.107030

PubMed Identifier: 36519749

Publication URI: http://europepmc.org/abstract/MED/36519749

Type: Journal Article/Review

Volume: 124

Parent Publication: Contemporary clinical trials

ISSN: 1551-7144